Nebenwirkungen · Besponsa
BESPONSA 1 mg powder for concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 14
HOS-135329 · Präparat HOS-097690
In the adult pivotal study (N=164), infections, including serious infections, some of which were life-threatening or fatal, were reported in 79 (48%) patients. The frequencies of specific infections were: sepsis, and bacteraemia (17%), lower respiratory tract infection (12%), upper respiratory tract infection (12%), fungal infection (9%), viral infection (7%), gastrointestinal infection (4%), skin infection (4%), and bacterial infection (1%). Fatal infections, including pneumonia, neutropenic sepsis, sepsis, septic shock, and pseudomonal sepsis, were reported in 8 (5%) patients.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-18T14:13:00Z · SHA-256 1da1da098efc99e357cf89eb2defe860d1474c0a37df3a9adcb8ba63218e0f18 · Passage c7eb88cbfecf8348e113569dac33847f170b4af4178dbf63ad53e61dd9acb485 · Zeichen 15023–15608 im Abschnitt